Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

(2010) Michaela Diamant et al.   LANCET

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Family Practices' Achievement of Diabetes Quality of Care Targets and Risk of Screen-Detected Diabetic Retinopathy

(2010) Martin C. Gulliford et al.   PLoS One

Trends in the prevalence and incidence of diabetes in the UK: 1996-2005

(2009) E L M. Gonzalez et al.   JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH

Cost-effectiveness of reducing wait times for cataract surgery in Ontario

(2008) Robert B. Hopkins et al.   CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE

Screening Uptake in a Well-Established Diabetic Retinopathy Screening Program: The role of geographical access and deprivation

(2008) G. P. Leese et al.   DIABETES CARE

Health utility values associated with diabetic retinopathy

(2008) A. Lloyd et al.   DIABETIC MEDICINE

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

Clinical Risk Factors, DNA Variants, and the Development of Type 2 Diabetes

(2008) Valeriya Lyssenko et al.   NEW ENGLAND JOURNAL OF MEDICINE